Nipocalimab, an anti-FcRn monoclonal antibody, in participants with moderate to severe active rheumatoid arthritis and inadequate response or intolerance to anti-TNF therapy: results from the phase 2a IRIS-RA study
Article in RMD Open (June 2024)
The most recent citing publications are shown below. View all 2 publications that cite this research output on Dimensions.
Article in RMD Open (June 2024)
Article in JCI Insight (May 2024)